CONCLUSION
In summary, we developed a population PKPD model for oxypurinol in Hmong
participants with gout and/or hyperuricemia who take allopurinol. Body
mass and renal function are key determinants for oxypurinol clearance
and baseline SU, which aligns with previous findings. We also identified
SNPs that can impact the oxypurinol clearance and its SU-lowering
effect, which could have clinical importance. Considering all the
important covariates, we propose a maintenance dose scheme of
allopurinol to achieve target SU in the Hmong population that could help
to better manage gout in this population, which exhibits a high
prevalence of gout.67,68 The validity of this dosing
scheme will require further study. However, we believe this study
represents an important step in demonstrating the value of clinical
trials including unique, under-represented populations who are at high
risk for clinical consequences from hyperuricemia and gout and could
benefit from effective ULT.